Butterfly-Shaped Coumarin Molecules Show Promise as Dual Alzheimer’s Enzyme Blockers

Chemists have crafted a family of butterfly-shaped molecules built from two coumarin rings joined by a single carbon bridge, and the compounds are showing a rare double talent: they can rein in both acetylcholinesterase and monoamine oxidase-B, two enzymes that sit at the heart of Alzheimer’s disease pathology. The work, published in Results in Chemistry, combines classic synthetic organic chemistry with high-resolution crystallography and computational docking to trace exactly why the smallest halogen atoms on the molecules deliver the biggest biological punch.

Coumarin, formally known as 2H-chromen-2-one, is a scaffold that nature and medicinal chemists have exploited for decades. It appears in natural products such as esculetin, decursinol, and scopoletin, each carrying a portfolio of pharmacological effects ranging from antioxidant and anti-inflammatory activity to documented acetylcholinesterase inhibition. Because the coumarin core offers six positions for chemical substitution, it provides an unusually flexible platform for building drug candidates. Previous biscoumarin derivatives, in which two coumarin units are linked through a central carbon, have already shown antiviral, urease-inhibitory, antiglycation, and even potential HIV-1 integrase blocking properties, making the scaffold a proven starting point for new therapeutic exploration.

The research team, led by Mohamed H. Helal and Ahmed M. El-Agrody with collaborators across Egypt and the United Arab Emirates, set out to make 4H-pyran-coumarin hybrids through a well-established three-component reaction between a 4-hydroxycoumarin, aromatic aldehydes, and malononitrile. Instead, the reaction took an unexpected turn. When 6-ethyl-4-hydroxy-2H-chromen-2-one was refluxed with a series of para-halogenated benzaldehydes in ethanol with piperidine as the base, the anticipated pyran-coumarin products never materialized. Rather than forming the hypothetical intermediate that would have reacted with malononitrile, the coumarin attacked the aldehyde twice, delivering a family of bis-coumarins in which a central methine carbon bridges two coumarin units, each bearing a pendant 4-halophenyl group with fluorine, chlorine, bromine, or iodine at the para position.

The mechanistic story behind this surprise is a textbook cascade of organic transformations. Piperidine first abstracts the acidic proton from the keto tautomer of the coumarin, generating a resonance-stabilized enolate. That nucleophile attacks the aldehyde carbonyl, and the resulting hydroxyl intermediate dehydrates to an alpha,beta-unsaturated species. A second coumarin enolate then performs a 1,4-Michael addition onto this activated double bond, forging a new carbon-carbon bond, and a final proton shift delivers the bis-coumarin product while regenerating the base catalyst. The sequence elegantly explains why the two-component condensation outcompeted the intended three-component pathway.

Structural proof came from an arsenal of spectroscopic techniques. Infrared spectra revealed hydroxyl stretches near 3275 per centimeter and lactone carbonyl absorptions around 1772 per centimeter, while proton and carbon NMR confirmed the characteristic methine, methylene, and methyl signals of the ethyl substituents. Advanced two-dimensional experiments, including COSY, HSQC, HMBC, and DEPT spectra, allowed the team to assign all sixteen carbon resonances unambiguously. The decisive evidence, however, arrived from single-crystal X-ray diffraction. All four derivatives crystallized in the monoclinic space group P 21/n, and the structures revealed a striking butterfly-like arrangement in which the two coumarin moieties adopt an anti-conformation locked by strong intramolecular hydrogen bonds between the 4-hydroxyl groups and the adjacent lactone carbonyl oxygens, with oxygen-oxygen distances of roughly 2.6 to 2.7 angstroms.

The crystallographic data also exposed a systematic trend across the halogen series. As the halogen grows from fluorine to iodine, the unit cell volume expands by nearly four percent, calculated densities climb from 1.311 to 1.543 grams per cubic centimeter thanks to the heavy atom effect, and the carbon-halogen bond lengths stretch from 1.368 to 2.096 angstroms, exactly as atomic radii predict. Hirshfeld surface analysis quantified the intermolecular contacts, showing that the fluorinated compound presents the most pronounced close-contact hot spots while the iodinated derivative offers the most balanced surface. Halogen-halogen contacts in the chloro, bromo, and iodo structures all fall short of the sum of van der Waals radii, confirming attractive type II halogen bonding that helps stitch the crystals together.

With the structures secured, the team turned to biology, and the results are what make this study genuinely exciting. Against acetylcholinesterase, measured with a modified Ellman assay, the chlorinated derivative emerged as the star performer with an IC50 of 1.484 micromolar, followed by the fluoro analogue at 2.535 micromolar. The bulkier bromine and iodine versions lagged behind at 3.757 and 5.240 micromolar respectively, all compared against the FDA-approved drug donepezil at 0.711 micromolar. The pattern reversed for monoamine oxidase-B, where the fluorinated compound took the lead with an IC50 of 1.006 micromolar, essentially matching the reference inhibitor tranylcypromine at 0.95 micromolar, while the chloro compound followed at 1.783 micromolar.

This divergence is the crux of the structure-activity relationship. Acetylcholinesterase possesses a narrow, twenty-angstrom gorge lined with aromatic residues, and docking simulations against the human enzyme structure 4EY7 showed that the chlorinated derivative spans the entire gorge, forming a halogen bond with the backbone of Ser293 and pi-pi stacking with Tyr341 and Tyr72. Chlorine, with its moderate van der Waals radius of about 1.75 angstroms and a significant sigma-hole, hits a Goldilocks balance of hydrophobic complementarity and directional bonding. Bromine and iodine, by contrast, trigger steric clashes with mid-gorge residues such as Phe295 and Met436, twisting the scaffold out of its optimal orientation. Monoamine oxidase-B presents a different challenge: a hydrophobic substrate cavity guarded by the dynamic Ile199 gate near the FAD cofactor. Here, fluorine’s small size lets the molecule slip through the gate and approach the flavin, while larger halogens are excluded to the entrance cavity, a picture that docking against the safinamide complex 4A79 vividly confirmed. Binding energies from the simulations correlated strongly with experimental potency, yielding R-squared values of 0.94 for acetylcholinesterase and 0.86 for monoamine oxidase-B.

Why does dual inhibition matter? The cholinergic hypothesis holds that Alzheimer’s symptoms stem from depleted acetylcholine, and every FDA-approved Alzheimer’s drug except memantine works by blocking acetylcholinesterase. Meanwhile, monoamine oxidase-B activity rises with age and in Alzheimer’s patients, generating hydrogen peroxide and free radicals that damage neurons and contribute to amyloid plaque formation. A single molecule that hits both targets could, in principle, address multiple facets of the disease simultaneously, a strategy increasingly favored for multifactorial conditions. The rigid, pre-organized anti-conformation enforced by the intramolecular hydrogen bonds may also enhance metabolic stability and membrane permeability, though those properties remain to be tested directly.

The road from micromolar enzyme inhibition to a medicine is long, and the authors are candid about the next steps: optimizing pharmacokinetics, testing in vivo efficacy in animal models, and designing hybrid derivatives that cross the blood-brain barrier more effectively. Future analogues might swap the 6-ethyl group for other small chains to fine-tune lipophilicity, or combine fluoro and chloro features to balance the distinct steric demands of the two enzymes. Still, the study delivers something rarer than a single hit compound. It provides a validated molecular template, a crystallographically grounded understanding of how halogen identity tunes potency at two different neurological targets, and a vivid demonstration that even a failed reaction can open an unexpected door, provided someone looks closely enough at the crystals that fall out of the flask.

Subject of Research: Synthesis and biological evaluation of halogenated bis(6-ethyl-4-hydroxy-2H-chromen-2-one) derivatives as dual acetylcholinesterase and monoamine oxidase-B inhibitors

Article Title: Synthesis of novel bis(6-ethyl-4-hydroxy-2 H -chromen-2-one) derivatives as potential acetylcholinesterase and monoamine oxidase inhibitors

Article References: Helal, M. H., Alrashdi, S., Alshareef, H. F., Moussa, Z., Elgammal, W. E., Halawa, A. H., Elhenawy, A. A., & El-Agrody, A. M. (2026). Synthesis of novel bis(6-ethyl-4-hydroxy-2H-chromen-2-one) derivatives as potential acetylcholinesterase and monoamine oxidase inhibitors. Results in Chemistry, 31, Article 103951. https://doi.org/10.1016/j.rechem.2026.103951

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103951

Keywords: coumarin, bis-coumarin, acetylcholinesterase, monoamine oxidase-B, Alzheimer's disease, enzyme inhibitors, X-ray crystallography, molecular docking, halogen bonding, structure-activity relationship, drug discovery, organic synthesis